Journal
BRITISH JOURNAL OF PHARMACOLOGY
Volume 165, Issue 3, Pages 643-658Publisher
WILEY
DOI: 10.1111/j.1476-5381.2011.01404.x
Keywords
perivascular adipose tissue; paracrine; vascular smooth muscle cell; adipokine; nitric oxide; hydrogen sulphide; reactive oxygen species; obesity; inflammation; vascular disease
Categories
Funding
- National Natural Science Foundation of China for Distinguished Young Scholars [30525045]
- National Basic Research Program of China [2009CB521902]
- National Science and Technology Major Project [2009ZX09303-002]
- Program of Shanghai Subject Chief Scientist [10XD1405300]
- Shanghai 'Shu Guang' Project [10GG19]
Ask authors/readers for more resources
Adipose tissue is the largest endocrine organ, producing various adipokines and many other substances. Almost all blood vessels are surrounded by perivascular adipose tissue (PVAT), which has not received research attention until recently. This review will discuss the paracrine actions of PVAT on the growth of underlying vascular smooth muscle cells (VSMCs). PVAT can release growth factors and inhibitors. Visfatin is the first identified growth factor derived from PVAT. Decreased adiponectin and increased tumour necrosis factor-a in PVAT play a pathological role for neointimal hyperplasia after endovascular injury. PVAT-derived angiotensin II, angiotensin 17, reactive oxygen species, complement component 3, NO and H2S have a paracrine action on VSMC contraction, endothelial or fibroblast function; however, their paracrine actions on VSMC growth remain to be directly verified. Factors such as monocyte chemoattractant protein-1, interleukin-6, interleukin-8, leptin, resistin, plasminogen activator inhibitor type-1, adrenomedullin, free fatty acids, glucocorticoids and sex hormones can be released from adipose tissue and can regulate VSMC growth. Most of them have been verified for their secretion by PVAT; however, their paracrine functions are unknown. Obesity, vascular injury, aging and infection may affect PVAT, causing adipocyte abnormality and inflammatory cell infiltration, inducing imbalance of PVAT-derived growth factors and inhibitors, leading to VSMC growth and finally resulting in development of proliferative vascular disease, including atherosclerosis, restenosis and hypertension. In the future, using cell-specific gene interventions and local treatments may provide definitive evidence for identification of key factor(s) involved in PVAT dysfunction-induced vascular disease and thus may help to develop new therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available